Advances in nutrition (Bethesda, Md.)Sep 17, 2026

Epigenetic Memory May Explain Weight Regain After Incretin Treatment

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 18, 2026

Abstract

Treatment discontinuation of incretin receptor agonists is associated with rapid weight regain.

The phenomenon termed the 'Incretin Mirage' indicates that weight loss from drug treatment masks underlying metabolic changes from obesity.
Persistent epigenetic marks in adipocytes may sustain obesity-related dysfunction and altered appetite signaling despite weight loss.
The 'Epigenetic Detent' concept connects epigenetic memory in fat cells with neuroendocrine changes, contributing to the body's resistance to lasting weight loss.
When pharmacological treatment is stopped, a defended high-adiposity set-point may drive rapid weight regain.
Long-term weight management could require integrating lifestyle changes with advanced therapies aimed at modifying epigenetic marks.

Simplified

While incretin receptor agonists deliver profound weight loss, clinical data reveal a consistent challenge: treatment discontinuation routinely triggers rapid weight regain. We define this phenomenon as the "Incretin Mirage"-a state where pharmacologically induced weight reduction temporarily conceals the persistent metabolic and neuroendocrine adaptations established during chronic obesity. Despite a lower body mass, key drivers of the disease, including adipocyte dysfunction and altered appetite signaling, retain a molecular imprint of obesity driven by persistent epigenetic marks. To explain why the body aggressively resists sustained weight loss after treatment cessation, we introduce the "Epigenetic Detent." This novel conceptual mechanism links adipocyte epigenetic memory with neuroendocrine plasticity to preserve a high-adiposity set-point. Consequently, the moment pharmacological suppression is lifted, this persistently defended set-point serves as a potential driver of weight regain. Achieving a durable therapeutic response therefore requires moving beyond transient appetite suppression. We advocate for a coordinated, multi-tiered strategy that couples lifestyle and environmental restructuring with next-generation epigenetic therapies capable of erasing these cellular marks and achieving a complete cellular metabolic reset.

Full Text

Full text is available at the source.

View Full Text ↗

Epigenetic Memory May Explain Weight Regain After Incretin Treatment

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief